

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INVIVO THERAPEUTICS CORPORATION, *et al.*,¹
Debtors.

Chapter 11

Case No. 24-10137 (MFW)

(Jointly Administered)

**NOTICE OF AGENDA FOR CONFIRMATION HEARING SCHEDULED
FOR JUNE 20, 2024, AT 3:00 P.M. (ET), BEFORE THE HONORABLE MARY F.
WALRATH OF THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

**This hearing will be conducted on Zoom.
Parties may attend the hearing remotely by registering at the link below no later than
JUNE 18, 2024 AT 4:00 P.M.**

**To attend a hearing remotely, please register using the eCourtAppearance tool
([available here](#)) or on the court's website at www.deb.uscourts.gov.**

***The deadline to register for remote attendance is 4:00 p.m. (prevailing Eastern Time) the
business day before the hearing unless otherwise noticed.***

MATTER GOING FORWARD:

1. [Motion of the Debtors for Entry of an Order \(I\) Approving the Disclosure Statement on an Interim Basis; \(II\) Scheduling a Combined Hearing on Final Approval of the Disclosure Statement and Plan Confirmation and Deadlines Related Thereto; \(III\) Approving the Solicitation, Notice and Tabulation Procedures and the Forms Related Thereto; and \(IV\) Granting Related Relief \[D.I. 140, filed April 8, 2024\]](#)

Objection Deadline: April 22, 2024 at 4:00 p.m. (ET)

Related Documents:

- A. [Joint Plan Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code](#)

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number, are: InVivo Therapeutics Corporation (6670) and InVivo Therapeutics Holdings Corp. (8166). The Debtors' mailing address is 1500 District Avenue, Burlington, MA 01803.



[D.I. 138, filed on April 8, 2024] (as amended, modified, revised or supplemented, the “Plan”)

- B. Disclosure Statement for the Joint Plan of Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code [D.I. 139, filed on April 8, 2024]
- C. Notice of Filing of Revised Joint Plan of Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code [D.I. 162, filed on April 29, 2024]
- D. Notice of Filing of Revised Disclosure Statement for the Joint Plan Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code [D.I. 163, filed on April 29, 2024]
- E. Order (I) Approving the Disclosure Statement on an Interim Basis; (II) Scheduling a Combined Hearing on Final Approval of the Disclosure Statement and Plan Confirmation and Deadlines Related Thereto; (III) Approving the Solicitation, Notice and Tabulation Procedures and the Forms Related Thereto; and (IV) Granting Related Relief [D.I. 165, entered on April 29, 2024]
- F. [Solicitation Version] Joint Plan of Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code [D.I. 168, filed on April 29, 2024]
- G. [Solicitation Version] Disclosure Statement for the Joint Plan of Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code [D.I. 169, filed on April 29, 2024]
- H. Notice of (A) Interim Approval of the Disclosure Statement and (B) Combined Hearing to Consider Final Approval of the Disclosure Statement and Confirmation of the Plan and the Objection Deadline Related Thereto [D.I. 172, filed on April 30, 2024]
- I. Amended Order (I) Approving the Disclosure Statement on an Interim Basis; (II) Scheduling a Combined Hearing on Final Approval of the Disclosure Statement and Plan Confirmation and Deadlines Related Thereto; (III) Approving the Solicitation, Notice and Tabulation Procedures and the Forms Related Thereto; and (IV) Granting Related Relief [D.I. 177, filed on May 6, 2024]
- J. Notice of (A) Interim Approval of the Disclosure Statement and (B) Combined Hearing to Consider Final Approval of the Disclosure

[Statement and Confirmation of the Plan and the Objection Deadline Related Thereto](#) [D.I. 178, filed on May 6, 2024]

- K. [Notice of Filing Plan Supplement](#) [D.I. 219, filed on June 11, 2024]
- L. [Declaration of Jeffrey Miller Regarding the Solicitation and Tabulation of Votes on the Debtors' Joint Chapter 11 Plan of Liquidation](#) [D.I. 225, filed on June 17, 2024]
- M. [Notice of Filing of Further Revised Joint Plan of Liquidation of InVivo Therapeutics Corporation and InVivo Therapeutics Holdings Corp. Pursuant to Chapter 11 of the Bankruptcy Code](#) [D.I. 226, filed on June 17, 2024]

Responses Received:

- N. Informal comments received from the Office of the United States Trustee (the "U.S. Trustee")

Status: The Debtors have revised the Plan to resolve the informal comments received by the U.S. Trustee, and the Debtors have received no other objections. This matter is going forward on an uncontested basis.

Dated: June 17, 2024
Wilmington, Delaware

LANDIS RATH & COBB LLP

/s/ Joshua B. Brooks

Matthew B. McGuire (No. 4366)
Joshua B. Brooks (No. 6765)
George A. Williams III (No. 6964)
919 Market Street, Suite 1800
Wilmington, Delaware 19801
Telephone: (302) 467-4400
Facsimile: (302) 467-4450
Email: mcguire@lrclaw.com
brooks@lrclaw.com
williams@lrclaw.com

Counsel for the Debtors and Debtors-In-Possession